INmune Bio

I Nmune Bio

Biotechnology, 980 N Federal Hwy, Boca Raton, Florida, 33432, United States, 11-50 Employees

inmunebio.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: 85********

Who is INMUNE BIO

INmune Bio Inc. is a clinical stage immuno-oncology company focused on harnessing the patients immune system to treat cancer. INKmune, the companys lead product, primes patients NK cells ...

Read More

map
  • 980 N Federal Hwy, Boca Raton, Florida, 33432, United States Headquarters: 980 N Federal Hwy, Boca Raton, Florida, 33432, United States
  • 2015 Date Founded: 2015
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $5 Million to $10 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2836 | NAICS Code: 541714 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from INMUNE BIO

INmune Bio Org Chart and Mapping

Employees

Parris Pope

Head of Medical Affairs

Scott Juda

Member Board of Directors/Chairman of Audit Commitee

David Moss

Chief Financial Officer

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding INmune Bio

Answer: INmune Bio's headquarters are located at 980 N Federal Hwy, Boca Raton, Florida, 33432, United States

Answer: INmune Bio's phone number is 85********

Answer: INmune Bio's official website is https://inmunebio.com

Answer: INmune Bio's revenue is $5 Million to $10 Million

Answer: INmune Bio's SIC: 2836

Answer: INmune Bio's NAICS: 541714

Answer: INmune Bio has 11-50 employees

Answer: INmune Bio is in Biotechnology

Answer: INmune Bio contact info: Phone number: 85******** Website: https://inmunebio.com

Answer: INmune Bio Inc. is a clinical stage immuno-oncology company focused on harnessing the patients immune system to treat cancer. INKmune, the companys lead product, primes patients NK cells (natural killer cells) to kill cancer. INmune is targeting residual disease, the cancer cells that survive initial treatments that return to cause the cancer relapse. By controlling residual disease, patients may live longer. Using a novel mechanism of action and a precision medicine approach, INKmune therapy should enhance NK cells ability to eliminate residual disease. Media coverage provided for informational purposes only and third party links provided as a resource. INmune Bio does not control the content of third parties. XPro1595, Quellor, LIVNate, INB03, INKmune and other drug candidates, have not yet been shown to be safe or effective, and has not been approved by any regulatory body.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access